MarginsXMarginsX
Home › Markets › LIPO

Lipella Pharmaceuticals Inc. (LIPO)

LIPO is quoted over the counter, not listed on an exchange. Lipella Pharmaceuticals Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · November 11, 2026
$0.0006
No trades since Nov 11, 2026; later closes repeat the last quote
1-year return
-99.9%
Market cap
$3K
Nano cap. From the Nov 11, 2026 last trade × 4.6M shares (10-Q cover page, Nov 13, 2025)
P/E and P/S
Net loss over the period · 0.0×
On trailing twelve months to September 30, 2025 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerLIPO, quoted over the counter
SEC CIK0001347242
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressPittsburgh, PA
Incorporated inDE

Warning signs

Cash runway
4.7 months
$1.9M cash at September 30, 2025
Share count, 1 year
+282.2%
2024-11-13 to 2025-11-13
Going-concern doubt
Yes
10-Q filed November 14, 2025
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2025-11-14
Cash and burn$1.9M cash; operating cash flow -$1.2M a quarter.Report 2025-09-30
Shares outstanding4,620,837 (2025-11-13); 1,208,919 a year earlier. the newest SEC cover-page count is from 2025-11-13; shares issued since then are not in these figures.Cover page 2025-11-13
Reverse splits, 3 years1; latest 1-for-8 on 2024-11-08Source 2024-11-08
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2025-10-06
AuditorUrish Popeck & Company, LLC, Pittsburgh, Pennsylvania, United StatesPCAOB Form AP 2025-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2025
2025-09-30
$0-$1.3M-$926K$1.9M$0$390K10-Q 2025-11-14
Q2 2025
2025-06-30
$87K-$1.3M-$1.4M$2.8M$0$470K10-Q 2025-08-14
Q1 2025
2025-03-31
$129K-$1.3M-$1.4M$4.2M$0$520K10-Q 2025-05-14
Q4 2024
2024-12-31
$174K-$1.4M-$990K$2.2M$0$536K10-K 2025-03-28
Q3 2024
2024-09-30
$80K-$1.4M-$653K$1.4M$0$484K10-Q 2025-11-14
Q2 2024
2024-06-30
$136K-$938K-$919K$1.2M$0$507K10-Q 2025-08-14
Q1 2024
2024-03-31
$146K-$1.2M-$1.4M$2.1MNo debt tags$477K10-Q 2025-05-14
Q4 2023
2023-12-31
$121K-$689K-$728K$3.3M$0$450K10-K 2025-03-28

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-04-04
Latest annual report10-K2025-03-28
Latest quarterly / interim10-Q2025-11-14
Latest current report8-K2026-07-15
Latest proxyPRE 14A2025-06-10

Source: SEC EDGAR submissions feed, 225 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier